Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 48,565 shares of the business's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $54.02, for a total value of $2,623,481.30. Following the transaction, the chief executive officer owned 48,565 shares of the company's stock, valued at $2,623,481.30. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Trading Up 2.8%
Kiniksa Pharmaceuticals International stock opened at $55.27 on Friday. The firm has a market capitalization of $4.23 billion, a P/E ratio of 61.41 and a beta of 0.17. Kiniksa Pharmaceuticals International, plc has a 1 year low of $24.85 and a 1 year high of $55.28. The business has a 50-day moving average of $46.40 and a 200-day moving average of $43.12.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same period in the previous year, the company earned $0.11 EPS. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.22 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Canaccord Genuity Group boosted their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an "outperform" rating in a research report on Wednesday. Zacks Research lowered Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research report on Friday, April 17th. Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Citigroup boosted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a "buy" rating in a research report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of "Moderate Buy" and an average price target of $60.86.
View Our Latest Stock Report on Kiniksa Pharmaceuticals International
Key Kiniksa Pharmaceuticals International News
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
- Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
- Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
- Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
- Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
- Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
Several institutional investors have recently bought and sold shares of KNSA. Qube Research & Technologies Ltd lifted its stake in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock valued at $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company's stock valued at $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Spruce Street Capital LP bought a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $17,943,000. Finally, SG Americas Securities LLC lifted its stake in Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company's stock valued at $22,333,000 after acquiring an additional 402,078 shares in the last quarter. Institutional investors own 53.95% of the company's stock.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
